Redhill Biopharma RDHL 深 沪
等待开盘 07-16 09:30:00 美东时间
0.7431
+0.004
+0.55%
华盛通- 最 高0.79
- 今 开0.74
- 成交量 26.90万股
- 最 低 0.74
- 昨 收 0.739
- 总市值 451.87万
- 52周最高 2.79
- 市盈率 静 --
- 换手率 4.42%
- 52周最低 0.637
- 委 比 45.83%
- 总股本 608.09万
- 历史最高 22220.00
- 量 比 3.52
- 振 幅 6.77%
- 历史最低 0.637
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RedHill Biopharma Announces Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewsw...
06-18 20:00
美股夜盘 | Everbright Digital Holding Ltd.涨52.51%，维珍银河涨13.44%
Sky Quarry, Inc.涨-8.90%；Tianci International Inc涨-6.96%；RedHill Biopharma Ltd. Sponsored ADR涨-5.66%
06-12 08:05
RedHill Biopharma shares are trading lower. The company announced the FDA has granted rare pediatric disease designation to opaganib for treatment of neuroblastoma.
RedHill Biopharma shares are trading lower. The company announced the FDA has g...
06-09 22:14
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Regentis Biomaterials (AMEX:RGNT) stock rose 128.9% to $2.93 during Tu...
06-09 20:05
RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus Disease
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential
06-02 20:10
Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies
04-30 19:12
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
04-27 20:14
RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of
04-22 20:06
RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled
02-25 20:11
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.
01-06 23:26
